A detailed history of Bank Of America Corp transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 276,737 shares of TERN stock, worth $2.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
276,737
Previous 38,364 621.35%
Holding current value
$2.85 Million
Previous $251,000 650.6%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.54 - $8.2 $1.08 Million - $1.95 Million
238,373 Added 621.35%
276,737 $1.88 Million
Q1 2024

May 15, 2024

SELL
$4.86 - $8.19 $99,396 - $167,501
-20,452 Reduced 34.77%
38,364 $251,000
Q4 2023

Feb 14, 2024

BUY
$3.37 - $6.86 $51,055 - $103,929
15,150 Added 34.7%
58,816 $381,000
Q2 2023

Aug 14, 2023

SELL
$7.35 - $13.29 $31,494 - $56,947
-4,285 Reduced 8.94%
43,666 $382,000
Q1 2023

May 12, 2023

BUY
$7.91 - $12.0 $364,935 - $553,632
46,136 Added 2541.93%
47,951 $567,000
Q4 2022

Feb 10, 2023

SELL
$4.62 - $10.18 $27,308 - $60,173
-5,911 Reduced 76.51%
1,815 $18,000
Q3 2022

Nov 14, 2022

SELL
$1.87 - $6.42 $19,414 - $66,652
-10,382 Reduced 57.33%
7,726 $46,000
Q2 2022

Aug 12, 2022

BUY
$1.5 - $3.0 $16,326 - $32,652
10,884 Added 150.66%
18,108 $44,000
Q1 2022

May 16, 2022

SELL
$2.83 - $6.7 $3,851 - $9,118
-1,361 Reduced 15.85%
7,224 $21,000
Q4 2021

Feb 08, 2022

BUY
$5.65 - $10.73 $19,509 - $37,050
3,453 Added 67.28%
8,585 $61,000
Q3 2021

Nov 15, 2021

BUY
$7.22 - $13.46 $1,133 - $2,113
157 Added 3.16%
5,132 $53,000
Q2 2021

Sep 13, 2021

BUY
$12.26 - $22.0 $60,993 - $109,450
4,975 New
4,975 $61,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $387M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.